Multicomponent non-pharmacological intervention to prevent delirium for hospitalised people with advanced cancer: Study protocol for a phase II cluster randomised controlled trial by Hosie, A et al.
1Hosie A, et al. BMJ Open 2019;9:e026177. doi:10.1136/bmjopen-2018-026177
Open access 
Multicomponent non-pharmacological 
intervention to prevent delirium for 
hospitalised people with advanced 
cancer: study protocol for a phase II 
cluster randomised controlled trial
Annmarie Hosie,1 Jane Phillips,1 Lawrence Lam,1 Slavica Kochovska,1 
Beverly Noble,1 Meg Brassil,1 Susan E Kurrle,2 Anne Cumming,3 
Gideon A Caplan,4,5 Richard Chye,6 Brian Le,7 E Wesley Ely,8 Peter G Lawlor,9 
Shirley H Bush,9 Jan Maree Davis,10 Melanie Lovell,1,2,11 Linda Brown,1 
Belinda Fazekas,1 Seong Leang Cheah,1 Layla Edwards,1 Meera Agar1
To cite: Hosie A, Phillips J, 
Lam L, et al.  Multicomponent 
non-pharmacological 
intervention to prevent delirium 
for hospitalised people with 
advanced cancer: study protocol 
for a phase II cluster randomised 
controlled trial. BMJ Open 
2019;9:e026177. doi:10.1136/
bmjopen-2018-026177
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
026177).
Received 21 August 2018
Revised 26 November 2018
Accepted 28 November 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Annmarie Hosie;  
 annmarie. hosie@ uts. edu. au
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Delirium is a significant medical 
complication for hospitalised patients. Up to one-third 
of delirium episodes are preventable in older inpatients 
through non-pharmacological strategies that support 
essential human needs, such as physical and cognitive 
activity, sleep, hydration, vision and hearing. We 
hypothesised that a multicomponent intervention similarly 
may decrease delirium incidence, and/or its duration and 
severity, in inpatients with advanced cancer. Prior to a 
phase III trial, we aimed to determine if a multicomponent 
non-pharmacological delirium prevention intervention is 
feasible and acceptable for this specific inpatient group.
Methods and analysis The study is a phase II cluster 
randomised wait-listed controlled trial involving inpatients 
with advanced cancer at four Australian palliative care 
inpatient units. Intervention sites will introduce delirium 
screening, diagnostic assessment and a multicomponent 
delirium prevention intervention with six domains of care: 
preserving natural sleep; maintaining optimal vision and 
hearing; optimising hydration; promoting communication, 
orientation and cognition; optimising mobility; and 
promoting family partnership. Interdisciplinary teams will 
tailor intervention delivery to each site and to patient need. 
Control sites will first introduce only delirium screening 
and diagnosis, later implementing the intervention, 
modified according to initial results. The primary outcome 
is adherence to the intervention during the first seven days 
of admission, measured for 40 consecutively admitted 
eligible patients. Secondary outcomes relate to fidelity 
and feasibility, acceptability and sustainability of the study 
intervention, processes and measures in this patient 
population, using quantitative and qualitative measures. 
Delirium incidence and severity will be measured to inform 
power calculations for a future phase III trial.
Ethics and dissemination Ethical approval was obtained 
for all four sites. Trial results, qualitative substudy findings 
and implementation of the intervention will be submitted 
for publication in peer-reviewed journals, and reported at 
conferences, to study sites and key peak bodies.
trial registration number ACTRN12617001070325; Pre-
results.
IntroduCtIon 
Delirium is a serious acute neurocogni-
tive disorder and medical complication for 
people with advanced cancer receiving palli-
ative care in hospital, where it occurs for up 
to one in two patients and is reversible in only 
up to half of cases, at best.1–3 It causes sudden 
disruption to attention and cognition, such as 
memory and language deficit, disorientation 
and perception.1 During delirium, feelings 
of fear, humiliation, confusion and isolation 
are common,4 at a time when connection 
with family, friends and health professionals 
is important and highly valued.5 Family expe-
riences high levels of distress as a result.5 
Delirium is further associated with increased 
falls, pressure areas, longer-term cognitive 
strengths and limitations of this study
 ► Strengths are the cluster randomised controlled trial 
design; inclusion of patient and family perspectives; 
and sponsorship by the Palliative Care Clinical Trials 
Collaborative, a national, multisite clinical trials 
group which provides rigorous research governance.
 ► A limitation is that site and research staff will not be 
blinded to the intervention.
 ► The study is being conducted in Australian palliative 
care inpatient settings and will include only patients 
with advanced cancer, limiting the generalisability 
of results for other settings and people with other 
advanced illnesses.
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and functional decline, duration of hospital stay, mortality 
and healthcare costs.6–8 
Despite the incidence of delirium and its profound 
impacts on people with advanced illness, there are limited 
treatment options and, to date, no effective pharmacolog-
ical intervention.9–11 Nor have evidence-based processes 
for delirium prevention, recognition or assessment been 
translated in palliative care units.12 13 The most effective 
strategy for delirium in older patients across a range of 
hospital settings is prevention through non-pharmacolog-
ical strategies to meet essential needs, such as physical and 
cognitive activity, sleep, hydration, vision and hearing. 
When implemented as a ‘multicomponent intervention’, 
these strategies have reduced delirium incidence by 
one-third.9 14 A meta-analysis (n=4267) of randomised or 
matched trials of non-pharmacological prevention strate-
gies reported significant reduction in delirium incidence, 
with the odds of delirium 53% lower in the intervention 
group compared with controls (OR 0.47, 95% CI 0.38 to 
0.58, p<0.001).14 A Cochrane review of 39 randomised 
controlled trials (RCTs; n=16 082) of non-pharmacolog-
ical, medication or anaesthetic interventions reported 
that seven non-pharmacological intervention studies 
(n=1950) reduced delirium incidence (relative risk (RR) 
0.69, 95% CI 0.59 to 0.81), while evidence for most medi-
cation and anaesthetic interventions was uncertain.9 
There was moderate quality evidence that the non-phar-
macological interventions reduced length of hospital 
admission and improved the likelihood of return to inde-
pendent living, with low-quality evidence of decreased 
delirium duration and severity.9 Studies of non-pharmaco-
logical interventions for delirium have mainly focused on 
older patients, yet often excluded patients with advanced 
cancer and other life-threatening illnesses.15 Also, strat-
egies within the interventions were diverse, some were 
better operationalised than others and not all used a 
randomised design.14
The one study testing a non-pharmacological delirium 
prevention intervention for people with advanced cancer 
(n=1516) in seven Canadian specialist palliative care 
inpatient units reported no statistically significant differ-
ence in delirium incidence, total days in delirium, dura-
tion of first episode, severity or delirium-free survival.16 
Strategies were fewer and less targeted to essential needs 
of patients than those reported in the more recent 
meta-analysis and Cochrane review9 14; and included (i) 
orientating patients to time, person and place each shift; 
(ii) informing family about delirium, its symptoms and 
prevention of confusion; and (iii) assessing pharmacolog-
ical risk factors for delirium before querying physicians 
about consequent planned medication change. There 
also was inadequate rate and timeliness of completion of 
the primary measure, the Confusion Assessment Method. 
While adherence to the intervention was >80%, there was 
no difference in overall use of psychoactive medication 
between the two arms. Given that such medication is asso-
ciated with delirium,17 18 this factor may partly explain the 
study’s negative results.16
There are possible barriers to implementation of 
non-pharmacological delirium prevention strategies 
for people with advanced cancer. These include their 
common frailty and fatigue which reduces capacity to 
participate in activities such as exercise. Patients and 
family may not realise the serious risks associated with 
an episode of delirium or prioritise prevention strategies 
without this knowledge. Some clinicians may perceive 
that delirium is inevitable and innocuous in advanced 
cancer and palliative care contexts19 20; and presume 
that preventing delirium is not possible, necessary or 
likely to be effective. Clinicians historically have relied 
on pharmacological intervention for delirium, rather 
than intentionally striving to prevent delirium through 
non-pharmacological means. With competing demands 
and without evidence of effectiveness, hospital managers 
may not value the importance of preventing delirium 
or allocate the required resources or personnel for 
non-pharmacological strategies, particularly for people 
approaching the end of their life.
Despite these barriers, the remit of palliative care 
to help patients live as actively as possible makes it 
important to study whether delirium can be prevented 
during advanced cancer. Based on the body of research 
conducted with older people in hospital,9 14 we hypothe-
sised that a similar multicomponent intervention would 
reduce delirium incidence and/or decrease its dura-
tion and severity for this inpatient population. Given 
the above-noted possible challenges to implementation, 
piloting the intervention and study design was required 
prior to testing the hypothesis in a phase III (efficacy) 
trial.
AIM And objECtIvEs
To determine if a multicomponent non-pharmacological 
delirium prevention intervention is feasible and accept-
able for inpatients with advanced cancer.
The objectives are to:
1. Develop a multicomponent non-pharmacological de-
lirium prevention intervention (‘non-pharmacologi-
cal delirium prevention intervention’), derived from 
highly efficacious interventions for older adults in hos-
pital, for people with advanced cancer and palliative 
care inpatient unit settings.
2. Describe the strategies used by participating sites 
to implement the delirium measurement tools and 
non-pharmacological delirium prevention interven-
tion.
3. Determine if a non-pharmacological delirium preven-
tion intervention is feasible, acceptable and deliver-
able with high adherence and fidelity in oncology and 
palliative care units.
4. Determine the feasibility and design of a phase III trial 
to test the efficacy of the non-pharmacological deliri-
um prevention intervention in people with advanced 
cancer in hospital.
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A phase II, cluster RCT with a waitlist control.21 Partic-
ipating sites will be randomised to the intervention 
(screening and immediate implementation of inter-
vention) or control (screening and waitlist to the modi-
fied intervention) (figure 1).
The use of this design in the phase II trial was to inform 
the feasibility and design, delivery methods and power 
calculations of a future multisite phase III cluster RCT. A 
cluster approach was chosen because the proposed inter-
vention is more suited to implementation at a site level, 
and a traditional RCT design would risk contamination 
in the control arm. The use of a cluster RCT design is an 
advance on prior studies of non-pharmacological preven-
tion interventions that used non-randomised designs. 
A waitlist control arm was chosen as key stakeholders at 
interested sites considered that the delirium prevention 
strategies were important; that participation in a trial that 
enabled access to the intervention was more appealing 
and ethically sound; and that the intervention strategies 
were well established as effective in other hospital settings 
and the potential benefits were clear, in principle. The 
waitlist control adds to the resource and time require-
ments of the trial, but will allow the intervention and 
study processes to be modified and/or refined at the two 
waitlist control sites, should initial results indicate that 
this is required.21
sites (clusters) and patient population
The participating sites are four Australian palliative 
care units, where approximately 75% of patients have a 
primary diagnosis of advanced cancer.22
In line with the cluster RCT design, consent to partic-
ipate was obtained at the site level from the person with 
the delegation to approve participation. Data will be 
collected for all admitted patients aged >18 years with 
a diagnosis of advanced cancer, for which no individual 
patient consent will be required.
Intervention
Intervention sites will implement (i) delirium screening, 
(ii) delirium diagnosis assessments and (iii) the multi-
component delirium prevention intervention.
Bedside nurses will undertake the Nursing Delirium 
Screening Scale (Nu-DESC)23 for all eligible patients 
at the end of every shift. Within 24 hours of the patient 
assessed as having a Nu-DESC score >2, a trained physi-
cian will apply Diagnostic and Statistical Manual of 
Mental Disorders, Fifth edition (DSM-5) diagnostic 
criteria for delirium,1 operationalised using the Delirium 
Rating Scale-Revised-1998 (DRS-R-98).24 These processes 
currently are not routine at the participating sites and 
therefore will be additional to usual care.
The multicomponent delirium prevention interven-
tion involves five domains of care that, when delivered in 
combination, significantly reduced delirium incidence in 
older hospitalised patients in previous clinical trials.9 14 
We added family partnership as the sixth domain as it 
was recommended by our consumer investigators and an 
expert working group, is highly valued by patients and 
family members,5 25 and has been identified as essential 
by the Australian Commission for Safety and Quality in 
Healthcare in a new Delirium Standard, if preferred by the 
patient.26 We did not include a pharmacological compo-
nent (such as minimising polypharmacy) because there 
was less evidence that this effectively prevents delirium 
compared with clinical care that which addresses funda-
mental human needs for physical and cognitive activity, 
sleep, hydration, vision and hearing.9, 14
The delirium prevention intervention will be delivered 
to all eligible patients for the first seven days of admission 
by members of the interdisciplinary team, family care-
givers and volunteers. The domains and strategies of the 
multicomponent intervention are presented in table 1.
Control sites will initially implement only delirium 
screening and diagnosis. Once the intervention sites 
achieve their sample, control sites will implement the 
intervention.
All sites will continue usual care with respect to treat-
ment of patients with delirium.
site engagement, education and training
The phase II trial will not predetermine delivery methods 
for the intervention, instead observing the methods of 
each site in order to learn about their team’s established 
practice, as well as what practices they needed to establish. 
Engagement of site staff and volunteers will be guided by 
Michie’s Behaviour Change Wheel, an evidenced-based 
framework for changing health-related behaviours.27 
Each site will form an interdisciplinary working group 
of medical, nursing, allied health, pastoral care, volun-
teer coordinator and managerial staff. The function of 
the working groups will be to determine how to deliver 
the intervention with the available resources, composi-
tion and capabilities of their site team.27 Working group 
members will communicate the study to the whole team, 
Figure 1 Study diagram of standardised delirium screening at all sites+delirium prevention strategies at intervention sites; 
control sites waitlisted for intervention. *Modified if required. 
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promote the delirium screening, diagnosis and prevention 
strategies, and inform patients and family about delirium 
and the prevention strategies. Site teams will be encour-
aged to tailor the intervention strategies to each patient’s 
assessed needs and preferences to ensure person-centred 
care, as well as to adopt simple and feasible methods of 
delivery and documentation of the intervention.
Education and training of site staff and volunteers in 
the delirium screening and prevention strategies will 
be standardised, interdisciplinary and based on Biggs’ 




 ► Offer ear plugs to patients with low risk of falls
 ► Offer eye shades to patients with low risk of falls
 ► Reduce noise outside patient rooms during 21:00-06:00
 ► Normal day–night light variation in room and unit
 ► Exposure to natural light during daylight hours
 ► Schedule care activities to allow uninterrupted sleep during 
the night
 ► Avoid caffeine after 16:00
 ► The patient wears ear plugs at night
 ► The patient wear eye shades at night
 ► Room curtains/blinds are open during the day
 ► Room lights are off or minimised at night
 ► The patient spends time outside during the day
 ► The patient drinks no caffeinated drinks after 16:00
 ► The patient reports uninterrupted night-time sleep
Maintain optimal 
sensory perception
 ►  Assess hearing
 ► Assist with and reinforce use of hearing aids and special 
communication techniques
 ► Ear wax clearing as needed
 ► Assess need for visual aids (glasses, magnifying lenses)
 ► If needed, ask family to provide for the patient
 ► Assist with and reinforce use of visual aids
 ► The patient has their hearing assessed
 ► The patient has ear wax cleaning
 ► The patient wears functioning hearing aids
 ► The patient has their vision assessed
 ► The patient wears their glasses appropriately
 ► The patient uses visual aids
Optimise hydration  ► Encourage oral fluids
 ► Physical assistance with drinks and meals, as required
 ► Drinking aids, as required
 ► Be alert and respond to reversible causes of poor oral intake 
within 24 hours, for example, nausea, vomiting, drowsiness, 
sore mouth
 ► The patient is encouraged to drink
 ► The patient is assisted with meals
 ► Drinking aids are provided, for example, straws






 ► Interpreter and translation for people of non-English speaking 
background
 ► Greet the patient by name
 ► Introduce self by name and role
 ► Refer to person, time and place when talking with the patient
 ► Time aids in room for example, watch, personal or wall clock; 
wall, desk or electronic calendar
 ► Update in-room whiteboards daily with date, day, place, 
reason for admission, team member names, schedule
 ► Minimise number of transfers to other beds or rooms within 
the unit
 ► Discuss current events with the patient
 ► Encourage the patient to reminisce and talk
 ► Encourage the patient to engage in cognitively stimulating 
activities
 ► Interpreter is available and used
 ► Orientating information is translated into the 
patient’s native language
 ► The patient can see the time, day, date and month 
in their room
 ► The patient remains in the same bed location within 
the unit
 ► The patient discusses current events
 ► The patient reminisces and/or talks about their life 
and family
 ► The patient spends time in cognitively stimulating 
activities, for example, reading, puzzles, games, 
knitting, music
 ► Cognitive stimulating activities are in the patient’s 
care plan
Optimise mobility  ► Minimise use of tethers, for example, intravenous line, 
indwelling catheter, drain, oxygen
 ► Minimise use of physical restraints, for example, bed rails, 
lock-in chair tables, vest restraints, limb restraints
 ► Encourage and/or assist the patient to undertake physical 
activity throughout the day according to their capacity
 – Level 0: no activity planned (state reason),
 – Level 1: active range of movement exercises in bed 
and/or sitting position in bed, for example, regular bed 
adjustment, assistance with re-positioning
 – Level 2: assistance to sit on the side of the bed
 – Level 3: sitting out of bed in a chair, standing
 – Level 4: walking (marching in place, independent or 
assisted walking around room and unit)
 – Level 5: attend inpatient gym, walking outside of unit
 ► The patient is free of tethers
 ► The patient is free of physical restraint
 ► The patient moves and/or exercises to their optimal 
capacity
Family partnership  ► Ask family about the patient’s baseline cognition
 ► Inform the patient and family about delirium risk
 ► Inform the patient and family about delirium prevention 
strategies and invite participation
 ► Family are asked about the patient’s baseline 
cognition on admission
 ► Delirium information brochure is provided to the 
patient and family
 ► Verbally inform of delirium risk and prevention
 ► Patients and family are invited to participate in 
delirium prevention strategies
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educational model.28 29 This model will align educational 
objectives and methods with the delirium learning needs 
of staff, and promote critical reflection on attitudes, prac-
tice and functional knowledge of the complexities of 
caring for a person with advanced cancer in hospital.28 29 
Education and training will take place for 2 months prior 
to data collection. A brief, simple study overview manual 
also will be developed.
Study investigators and/or project staff will attend sites 
to (i) promote fidelity to the study processes and aims; 
(ii) assist with education and training activities; (iii) 
resolve issues that delay implementation of the inter-
vention or threaten its integrity; (iv) act as a ‘delirium 
resource person’ and (v) support and encourage site staff 
and volunteer participation in the intervention.
The frequency, duration and mode of administration of 
education and training will be determined prior to imple-
menting delirium screening, diagnosis and prevention 
strategies in collaboration with participating sites, then 
standardised for each. Based on the learnings obtained 
in this phase II trial, we will develop a replicable stan-
dardised education resource for the phase III trial.
randomisation
In keeping with the method of the anticipated phase III 
trial, we will use a permuted block randomisation method 
with various block sizes to allocate sites to the intervention 
or waitlist control. Randomisation will be performed by 
the study statistician (LL) from the coordinating centre, 
the University of Technology Sydney (UTS).
blinding and avoidance of contamination
The study design and nature of the intervention means 
that blinding of site staff will not be possible. Written infor-
mation for patients and family caregivers will provide only 
general information about the study aims, rather than 
specifics of the design or site allocation. Attention will be 
focused on research nurse training and standardisation 
of data collection to limit the potential for bias.
To avoid contamination between sites, personnel 
collecting data at an intervention site will not collect data 
in a control site, and vice versa. Site investigators, research 
nurses and project staff will be asked not to discuss the 
intervention in joint tele-meetings with control sites. 
Clinicians at control sites initially will receive information 
and training on delirium screening and diagnosis only, 
and only general information about the prevention inter-
vention in discussions and promotion, until they move 
into the intervention phase.
data collection
Research nurses will collect baseline data from sites’ 
most recent Palliative Care Outcomes Collabora-
tive (PCOC) report (a national programme which 
measures and benchmarks patient outcomes in pallia-
tive care using standardised clinical assessment tools)23 
(figure 2) and from key personnel. Research nurses will 
screen consecutively admitted patients for eligibility, 
collect delirium screening and diagnostic assessment 
measures for enrolled patients and record these in a 
Case Report Form (CRF). At intervention sites, specially 
designed checklists will capture family caregivers, staff 
and volunteers’ delivery of delirium prevention strate-
gies within each domain of the multicomponent inter-
vention (table 1), as well as who delivered it. From this, 
we will determine the level of involvement of family 
caregivers, interdisciplinary staff and volunteers for 
each strategy and domain. Whenever the patient does 
not receive the strategy, the reason will be recorded 
according to the following categories:
 ► Not required
 ► Patient choice
 ► Not clinically appropriate
 ► Not possible with current resources
 ► Other
At study completion, the project team will collect 
PCOC data for the study time frame (age, gender, 
country of birth, preferred language, Aboriginal or 
Torres Strait Islander status, primary diagnosis, length of 
stay, performance status (Australian-modified Karnofsky 
Performance Status (AKPS)30 and Resource Utilisation 
Groups—Activities of Daily Living (RUG-ADL)),31 palli-
ative care phase).32 For the sustainability outcome, site 
research nurses will collect intervention adherence data 
at 6 months for all inpatients for 1 week.
Assessments
Figure 2 gives the schedule of study measures and time 
points; Box 1 provides information on the palliative care 
and delirium measures.
outcomes
The primary outcome is adherence to the intervention. 
A rate of at least 60% of patients having at least four 
completed domains for at least five of the first seven days 
of admission will be considered minimum evidence 
that the intervention is feasible without need for major 
modification of the intervention or its delivery methods. 
Endpoints will be at completion of the intervention and 
modified intervention arms (figure 1).
We chose this moderate endpoint because of the 
potential patient, clinician and system-level challenges 
to the non-pharmacological strategies in the context 
of advanced cancer. Consensus by investigators was this 
endpoint would be the minimum to still have impact, 
realistic to achieve in practice, and ensure that further 
evaluation of this complex intervention was not prema-
turely stopped. The waitlist control design will allow two 
endpoints and thereby maximise the potential to reach 
this level of adherence to the intervention.
Secondary outcomes will further inform of the feasi-
bility, acceptability and potential efficacy of a phase III 
trial of the intervention in this patient population and 
setting, as follows:
1. Coverage: Delivery rate of the multicomponent inter-
vention to consecutive eligible patients admitted to 
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the unit, reasons why the intervention was not deliv-
ered, weekend coverage, measured via screening logs 
and CRFs.
2. Fidelity to delirium screening, diagnosis and the in-
tervention: Degree of alignment with the protocol, 
rationales for adaptation, rate of protocol deviations 
without reasons, measured via CRFs.
3. Methods, areas and levels of interdisciplinary involve-
ment in delivery of the intervention, measured via 
intervention checklist.
4. Feasibility and acceptability of the study intervention 
and measures for patients, caregivers, staff and volun-
teers, measured via brief interviews during and short-
ly after the intervention phase.
5. Sustainability of the intervention: Adherence will be 
measured for all inpatients over 1 week, 6 months af-
ter commencement of data collection at the interven-
tion sites.
6. Feasibility of the sample: Percentage of participants 
included in data collection, reasons for non-in-
clusion, time to achieve sample size, measured via 
screening logs and CRFs.
7. Number of people with advanced breast cancer 
admitted to the units, number of these who are in 
underserved populations (patients over 70, indige-
nous patients and culturally and linguistically diverse 
backgrounds), and the number who experience 
an episode of delirium (total, and in underserved 
Figure 2 Schedule of study measures and time points.43 Characteristics indicated with a * will be collected at baseline from 
the sites most recent Palliative Care Outcomes Collaborative (PCOC) report, and then again at study completion directly from 
PCOC for the specific time frame of data collection at each site. AKPS, Australian-modified Karnofsky Performance Status; 
DRS-R-98, Delirium Rating Scale-Revised-1998; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth edition; 
Nu-DESC, Nursing Delirium Screening Scale; RUG-ADL, Resource Utilisation Groups—Activities of Daily Living. 
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populations) (for the purposes of reporting to the 
trial funder, the National Breast Cancer Foundation).
8. Percentage completion of all study measures, mea-
sured via CRF.
9. Rate of patients with a positive delirium screen, mea-
sured according to a score of ≥2 on the Nu-DESC at 
least once during each 24 hours period.
10. Delirium incidence, measured at first onset accord-
ing to the DSM-5 diagnostic criteria for delirium ap-
plied within 24 hours of a positive delirium screen.
11. Delirium severity measured at first onset, using the 
DRS-R-98.
12. Number of falls, complaints and other adverse events 
related to the intervention.
substudy
A qualitative substudy will be conducted to obtain patient, 
family caregiver, staff and volunteer perceptions of the 
feasibility and acceptability of the intervention strategies 
(eg, receiving information from staff about delirium) 
and study measures via brief, semistructured interviews 
(figure 2).
Inclusion and exclusion criteria for the substudy
1. Patients will be included if they are aged 18 years or old-
er; have a diagnosis of advanced cancer; admitted to an 
intervention site and received the intervention; speak 
English or have access to a healthcare interpreter; and 
able to give fully informed written consent. Patients 
with advanced breast cancer will be purposively re-
cruited to participate in the interviews. Patients will be 
excluded if they have an AKPS30 score <30 and are in 
the ‘terminal’ Palliative Care Phase.32
2. Family caregivers will be included if they are aged 18 
years or older; identified as a caregiver of a patient who 
received the intervention; English speaking or have 
availability of a healthcare interpreter and able to give 
fully informed written consent.
box 1 description of study measures
The Australian-modified Karnofsky Performance Status was adapted from the Karnofsky Performance Status with good face validity and longitudinal 
test–retest reliability.30 The AKPS measures patients’ overall performance status, using 10-point increments along a scale of 100–10. A score of 100 
denotes normal function with no evidence of disease, decreasing to a minimum score of 10, assigned when patients are comatose or barely rousable. 
Routinely applied on an at least daily basis in most Australian inpatient unit palliative care services. The AKPS will be used to report the patient cohort’s 
performance status at participating sites.
The Resource Utilisation Groups—Activities of Daily Living31 is a validated functional assessment tool which assigns a score of 4–18, based on what a 
patient does in relation to bed mobility, transfers, eating and toileting, rather than they can do. Higher scores indicate the need for more assistance to 
undertake activities and that more resources are required to provide this assistance. Applied on an at least daily basis in most Australian inpatient unit 
palliative care services. The measure will be used to report the patient cohort’s functional status at participating sites.
The Palliative Care Phase32 classification is not a validated tool, but is applied on an at least daily basis in most Australian palliative care services to 
describe the needs of the patient and family and prompt a timely and appropriate clinical response. Phases are (i) stable (problems and symptoms are 
adequately managed and there is a plan of care); (ii) unstable (urgent intervention required because a new symptom or problem develops or an existing 
problem rapidly escalates); (iii) deteriorating (a gradual decline in function and worsening of an existing problem or development of a new but anticipated 
problem); (iv) terminal (death is likely within days); and (v) bereavement (post death support). The measure will be used to report the patient cohort’s 
palliative care needs at participating sites.
The Nursing Delirium Screening Scale24 was validated in an oncology inpatient population with a sensitivity of 85.7% and specificity of 86.8%.24 It is a 
brief (<1 min) five-item and low burden tool, incorporating nurses’ observation of disorientation, inappropriate behaviour, inappropriate communication, 
illusions/hallucinations and psychomotor retardation. Nurses assign a score of 0–2 for each item, giving a maximum score of 10. The psychomotor re-
tardation item improves recognition of hypoactive delirium,33 the most prevalent subtype in palliative care inpatient populations.3 The Nu-DESC has been 
used in previous research in inpatient palliative care populations11 and was considered feasible and acceptable by palliative care nurses.19 The Nu-DESC 
will be used by bedside nurses to screen patients for delirium every 8-hour shift.
The Diagnostic and Statistical Manual of Mental Disorders, Fifth edition diagnostic criteria for delirium are within the most current version of the American 
Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders.1 Criteria are (i) Disturbed attention and awareness; (ii) disturbance de-
veloped over a short period of time (usually hours to a few days), is a change from baseline attention and awareness and fluctuates in severity; (iii) an 
additional disturbance in cognition; (iv) disturbances in i and iii are not caused by another neurocognitive disorder nor occur in the context of severely 
reduced level of arousal; and (v) the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal, 
exposure to a toxin or has multiple aetiologies. Treating physicians will use the DSM-5 to determine a delirium diagnosis.
The Delirium Rating Scale-Revised-9825 is a 16-item delirium severity and diagnostic scale with scores of up to 46. It had high inter-rater reliability, 
sensitivity and specificity in the original validation study,25 high sensitivity and adequate internal consistency and factor validity in patients with cancer,34 
and has been used in research with palliative care inpatients.35 36 The DRS-R-98 was designed to measure a wider range of delirium symptoms than 
are contained within diagnostic criteria and in different settings had good discriminative capacity for all, including in a patient population with a high 
prevalence of dementia.37 38 Severity items are sleep–wake cycle disturbance; perceptual disturbances and hallucinations; delusions; lability of affect; 
language; thought process abnormalities; motor agitation; motor retardation; orientation; attention; short-term memory; long-term memory; and visu-
ospatial ability. Diagnostic items are temporal onset of symptoms; fluctuation of symptom severity; physical disorder. Information is obtained from all 
sources, including physical examination, history gathering and formal cognitive testing. Requires clinician training, with guidance for use contained within 
the tool. Trained treating physicians and nurses will use the DRS-R-98 to operationalise delirium diagnosis and measure delirium severity. We will use a 
diagnostic cut-off score of >15.38
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3. Site staff will be included if they are employed at an 
intervention site and involved in implementing the de-
lirium measures and/or the intervention.
4. Site volunteers will be included if they are aged 18 years 
or older, enrolled in a formal volunteer programme at 
an intervention site and involved in implementing the 
intervention.
substudy consent process
A researcher who is not a study investigator will obtain 
written informed consent from patients, family caregivers, 
staff and volunteers to participate in the brief interviews. 
For patients and family caregivers, the researcher will 
check with the clinical team to make sure the person 
meets the broad criteria for consideration of eligibility, is 
well enough and has given permission to be approached 
by a researcher, before introducing himself or herself to 
the person and explaining the study. For staff and volun-
teers, the researcher will consult with the site investigator 
before approaching potential participants.
Participant consent will be a process of information 
exchange between the researcher, the potential partic-
ipant and any other person the potential participant 
believes should be included in the discussion. Participant 
information sheets will be the basis for discussion and 
cover all procedures and possible benefits and burdens 
of participating. The potential participant will be given 
sufficient opportunity to consider the study and ask ques-
tions. Any questions will be addressed and answered fully. 
The completed consent form will be copied and one copy 
will be given to the participant, one copy inserted in the 
medical file (for patients) and one copy filed in study file.
Analysis
Statistical analysis of primary outcome (adherence)
Adherence will be calculated as the rate to which patients 
have completed domains on a daily basis for the first 
seven days of admission. Degree of adherence to indi-
vidual strategies will also be calculated as proportions.
Statistical analysis of secondary outcomes
Data on all outcomes will be summarised with descrip-
tive statistics including their distribution. Frequency and 
percentage will be used for summarising categorical vari-
ables and mean, SD, median and IQR for continuous vari-
ables. Delirium incidence and severity will be determined 
at both the intervention and control sites.
Qualitative analysis
Participant interviews will be analysed using thematic 
content analysis to identify emergent themes and trends 
related to participants’ perceptions of the feasibility and 
acceptability of the intervention elements and delirium 
measures.39
sample size
A sample size of four sites and 40 patient participants (10 
from each site) was considered sufficient for reasonable 
estimation of feasibility and percentage completion of 
study processes and measures during the first phase.40 
We will collect deidentified data on all eligible patients 
admitted to all sites until data are collected for 40 patients 
overall, with at least 20 in the intervention arm. If the 
intervention is found to need modification, data will be 
collected for a further 20 patient participants at the two 
waitlist control sites.
This sample size was based on that projected for the 
future phase III cluster RCT of the intervention with: two 
parallel arms, 50% delirium incidence in the control, 
30% delirium incidence in the intervention group, 
cluster size of 30 and intraclass correlation of 0.05, type I 
error rate of 5%, 80% power to reject the null hypothesis 
and 30% attrition. This calculation results in a projected 
phase III trial sample size of nine clusters and 280 patient 
participants.
For the substudy, sample size will be determined when 
data saturation is achieved.
trial monitoring
In addition to falls and complaints, all adverse events will 
be recorded. Site investigators will assess the adverse event, 
assign the degree of relationship to the intervention and 
provide information to the coordinating centre (UTS), and 
the approving Human Research Ethics Committee (HREC) 
if required. Adverse events will be followed until the event 
is resolved, can be explained or if the participant is lost to 
follow-up. Reports will contain details of follow-up investiga-
tions, results or other consultation. The investigator team 
will stop the study if reporting of adverse events indicates 
that major review of the study protocol is required. The UTS 
project team will report adverse event related to the interven-
tion to the PaCCSC Trial Management Committee (TMC) 
within 2 weeks of knowledge of the event. The TMC discus-
sions will be minuted, with actions detailed and reviewed at 
the subsequent meeting. The TMC chairperson’s report to 
the PaCCSC Scientific Committee will contain a summary 
of the discussions of the adverse event report and agreed 
outcomes.
data management
An Excel spreadsheet master index will contain confiden-
tial participant contact information and be the only link 
between individual site and patient participants and their 
allocated identification number (ID). Study data will be 
collected and stored on paper CRFs and electronic Excel 
spreadsheets and then entered onto and managed on a 
Research Electronic Data Capture (REDCap)41 database. 
Audio data from participant interviews will be identified 
only by ID, collected on a digital recording medium and 
stored temporarily at the study sites until uploaded to the 
REDCap database. Original files will then be destroyed. 
Data will be held, administered, checked and analysed 
at the coordinating site according to relevant PaCCSC 
Standard Operating Procedures. Errors detected during 
the data checking process will generate a site data report 
form recording details of the query and correction and 
resolution instructions. The database will be updated 
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according to site instructions via email to provide an audit 
trail of data changes. The coordinating site will maintain 
a register of data checks for monitoring purposes. Data 
collected at each site, such as CRFs, any corrected and 
amended data, copies of adverse incident reports and file 
notes, will be securely stored and identified by ID number 
only. All identifiable data (eg, signed consent forms) will 
be separately stored during the recruitment period. Site 
research staff will send copies of study documents (with 
the exception of signed consent forms) to the coordi-
nating site by registered mail for collation and archiving. 
All study documents will be stored in accordance with 
relevant state government regulations regarding the 
retention and disposal of participant records.
Patient and public involvement
The study rationale and processes were informed by the 
literature pertaining to patients’ experiences of delirium, 
as outlined in the introduction.4 5 Low-burden outcome 
measures, such as the Nu-DESC, were deliberately chosen in 
order to minimise the impact of the study on patients with 
advanced illness. No patients were directly involved in the 
design, recruitment to or conduct of the study. Two family 
caregiver consumers are associate investigators of the study 
(MB and BN). We will include the perspectives of patients 
about the feasibility and acceptability of the intervention 
through brief semistructured interviews. Investigators will 
not have access to the names or contact information of 
patient or family caregiver participants in order to directly 
provide feedback about the study to them. At study comple-
tion, a written and verbal report of the results and findings 
will be provided to the participating sites.
Ethics and dissemination
The study was approved by the South Western Sydney 
Local Health District HREC on 19 July 2017, reference 
number HREC/17/LPOOL/224; and ratified by the UTS 
HREC on 22 August 2017, reference number ETH17-
1697. Minor protocol amendments were approved on 
13 April 2018 (V1.1).
Reporting of this protocol adheres to the Standard 
Protocol Items: Recommended for Interventional Trials.42 
Reporting of results will adhere to the Consolidated Stan-
dards of Reporting Trials guidelines for cluster RCTs and 
non-pharmacological treatment trials.43 44 Reporting of 
the qualitative substudy and implementation findings 
will be guided by the Consolidated Criteria for Reporting 
Qualitative Research.45 A comprehensive dissemination 
strategy will ensure that the trial results (either positive 
or negative) inform future research and clinical practice. 
Dissemination will include publication in peer-reviewed 
journals, presentations at conferences, study sites and 
key peak bodies. The investigators have no publication 
restrictions.
strengths and limitations
The primary strengths of this study are the cluster RCT design 
and that it is supported by the PaCCSC, a national, multisite 
phase III clinical trials group which provides well-estab-
lished rigorous research governance and access to sites with 
research experience and capacity. The intervention includes 
family partnership, which is highly valued by both patients 
and family.5 26 We will obtain the perspectives of patients and 
family, which are largely absent in previous trials of multi-
component delirium interventions.15
Limitations include that site and research staff will 
not be blinded to the intervention. Active steps will be 
taken to minimise contamination between intervention 
and waitlist control sites. The study will be conducted in 
Australian palliative care inpatient settings and include 
only patients with advanced cancer, limiting the gener-
alisability of results for services in other geographical 
regions and healthcare systems, and for patients with 
other advanced illnesses.
trial status
The study has been approved by local health district and 
university HRECs, local governance approvals obtained, 
sites randomised, the 2-month training period completed 
and data collection is under way.
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